Is MIST or RLMD more profitable?

Relmada Therapeutics' return on equity of -47.52% beat Milestone Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Milestone Pharmaceuticals N/A -288.33% -58.27% Relmada Therapeutics N/A -47.52% -43.97%

Does the media refer more to MIST or RLMD?

In the previous week, Relmada Therapeutics had 1 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 5 mentions for Relmada Therapeutics and 4 mentions for Milestone Pharmaceuticals. Relmada Therapeutics' average media sentiment score of 1.40 beat Milestone Pharmaceuticals' score of 0.58 indicating that Relmada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Milestone Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relmada Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer CGC or MIST?

Milestone Pharmaceuticals has a consensus price target of $6.40, indicating a potential upside of 451.72%. Given Milestone Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Canopy Growth. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Canopy Growth 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Milestone Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71

Does the media prefer CGC or MIST?

In the previous week, Canopy Growth had 1 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 5 mentions for Canopy Growth and 4 mentions for Milestone Pharmaceuticals. Canopy Growth's average media sentiment score of 0.74 beat Milestone Pharmaceuticals' score of 0.58 indicating that Canopy Growth is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Canopy Growth 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Milestone Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MIST or AVIR more profitable?

Atea Pharmaceuticals' return on equity of -64.25% beat Milestone Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Milestone Pharmaceuticals N/A -288.33% -58.27% Atea Pharmaceuticals N/A -64.25% -57.12%

Does the media favor MIST or BIOA?

In the previous week, Milestone Pharmaceuticals had 2 more articles in the media than BioAge Labs. MarketBeat recorded 4 mentions for Milestone Pharmaceuticals and 2 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 1.82 beat Milestone Pharmaceuticals' score of 0.58 indicating that BioAge Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Milestone Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioAge Labs 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Milestone Pharmaceuticals (MIST) Competitors

$1.16 -0.03 (-2.52%)

As of 08/28/2026 04:00 PM Eastern

Compare

MIST vs. RLMD, CGC, AVIR, BIOA, and EYPT

Should you buy Milestone Pharmaceuticals stock or one of its competitors? Milestone Pharmaceuticals's main competitors and comparable companies include Relmada Therapeutics (RLMD), Canopy Growth (CGC), Atea Pharmaceuticals (AVIR), BioAge Labs (BIOA), and Eyepoint Pharmaceuticals (EYPT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Milestone Pharmaceuticals compare to Relmada Therapeutics?

Milestone Pharmaceuticals (NASDAQ:MIST) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

Relmada Therapeutics' return on equity of -47.52% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%
Relmada Therapeutics	N/A	-47.52%	-43.97%

86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are owned by institutional investors. 5.0% of Milestone Pharmaceuticals shares are owned by company insiders. Comparatively, 14.5% of Relmada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Relmada Therapeutics has lower revenue, but higher earnings than Milestone Pharmaceuticals. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.55M	93.17	-$63.06M	-$0.69	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A

Milestone Pharmaceuticals has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market.

In the previous week, Relmada Therapeutics had 1 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 5 mentions for Relmada Therapeutics and 4 mentions for Milestone Pharmaceuticals. Relmada Therapeutics' average media sentiment score of 1.40 beat Milestone Pharmaceuticals' score of 0.58 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Milestone Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relmada Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Milestone Pharmaceuticals currently has a consensus price target of $6.40, suggesting a potential upside of 451.72%. Relmada Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 177.14%. Given Milestone Pharmaceuticals' higher probable upside, equities research analysts clearly believe Milestone Pharmaceuticals is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Relmada Therapeutics beats Milestone Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Milestone Pharmaceuticals compare to Canopy Growth?

Canopy Growth (NASDAQ:CGC) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Canopy Growth has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market. Comparatively, Milestone Pharmaceuticals has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market.

In the previous week, Canopy Growth had 1 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 5 mentions for Canopy Growth and 4 mentions for Milestone Pharmaceuticals. Canopy Growth's average media sentiment score of 0.74 beat Milestone Pharmaceuticals' score of 0.58 indicating that Canopy Growth is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Canopy Growth	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Milestone Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Milestone Pharmaceuticals has a consensus price target of $6.40, indicating a potential upside of 451.72%. Given Milestone Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

3.3% of Canopy Growth shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 0.4% of Canopy Growth shares are owned by insiders. Comparatively, 5.0% of Milestone Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Milestone Pharmaceuticals has a net margin of 0.00% compared to Canopy Growth's net margin of -65.33%. Canopy Growth's return on equity of -21.91% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-65.33%	-21.91%	-14.34%
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%

Milestone Pharmaceuticals has lower revenue, but higher earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	$251.01M	1.79	-$190.29M	-$0.45	N/A
Milestone Pharmaceuticals	$1.55M	93.17	-$63.06M	-$0.69	N/A

Summary

Milestone Pharmaceuticals beats Canopy Growth on 11 of the 17 factors compared between the two stocks.

How does Milestone Pharmaceuticals compare to Atea Pharmaceuticals?

Milestone Pharmaceuticals (NASDAQ:MIST) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

Milestone Pharmaceuticals currently has a consensus price target of $6.40, suggesting a potential upside of 451.72%. Atea Pharmaceuticals has a consensus price target of $7.00, suggesting a potential upside of 30.60%. Given Milestone Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 5.0% of Milestone Pharmaceuticals shares are owned by company insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Atea Pharmaceuticals' return on equity of -64.25% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%
Atea Pharmaceuticals	N/A	-64.25%	-57.12%

Milestone Pharmaceuticals has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market.

Milestone Pharmaceuticals has higher revenue and earnings than Atea Pharmaceuticals. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.55M	93.17	-$63.06M	-$0.69	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A

In the previous week, Milestone Pharmaceuticals had 3 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 4 mentions for Milestone Pharmaceuticals and 1 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.89 beat Milestone Pharmaceuticals' score of 0.58 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Milestone Pharmaceuticals	Positive
Atea Pharmaceuticals	Very Positive

Summary

Milestone Pharmaceuticals beats Atea Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Milestone Pharmaceuticals compare to BioAge Labs?

Milestone Pharmaceuticals (NASDAQ:MIST) and BioAge Labs (NASDAQ:BIOA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 5.0% of Milestone Pharmaceuticals shares are held by insiders. Comparatively, 17.6% of BioAge Labs shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Milestone Pharmaceuticals has a net margin of 0.00% compared to BioAge Labs' net margin of -912.26%. BioAge Labs' return on equity of -28.99% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%
BioAge Labs	-912.26%	-28.99%	-27.09%

Milestone Pharmaceuticals presently has a consensus target price of $6.40, suggesting a potential upside of 451.72%. BioAge Labs has a consensus target price of $36.57, suggesting a potential upside of 278.98%. Given Milestone Pharmaceuticals' higher probable upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than BioAge Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Milestone Pharmaceuticals has higher earnings, but lower revenue than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.55M	93.17	-$63.06M	-$0.69	N/A
BioAge Labs	$8.99M	49.27	-$80.61M	-$2.38	N/A

Milestone Pharmaceuticals has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market. Comparatively, BioAge Labs has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market.

In the previous week, Milestone Pharmaceuticals had 2 more articles in the media than BioAge Labs. MarketBeat recorded 4 mentions for Milestone Pharmaceuticals and 2 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 1.82 beat Milestone Pharmaceuticals' score of 0.58 indicating that BioAge Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Milestone Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioAge Labs	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Milestone Pharmaceuticals beats BioAge Labs on 10 of the 16 factors compared between the two stocks.

How does Milestone Pharmaceuticals compare to Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are owned by company insiders. Comparatively, 5.0% of Milestone Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Milestone Pharmaceuticals has lower revenue, but higher earnings than Eyepoint Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	12.31	-$231.96M	-$3.74	N/A
Milestone Pharmaceuticals	$1.55M	93.17	-$63.06M	-$0.69	N/A

In the previous week, Eyepoint Pharmaceuticals had 6 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 10 mentions for Eyepoint Pharmaceuticals and 4 mentions for Milestone Pharmaceuticals. Milestone Pharmaceuticals' average media sentiment score of 0.58 beat Eyepoint Pharmaceuticals' score of 0.30 indicating that Milestone Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Milestone Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eyepoint Pharmaceuticals has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market. Comparatively, Milestone Pharmaceuticals has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market.

Eyepoint Pharmaceuticals presently has a consensus target price of $28.11, indicating a potential upside of 527.48%. Milestone Pharmaceuticals has a consensus target price of $6.40, indicating a potential upside of 451.72%. Given Eyepoint Pharmaceuticals' higher possible upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Milestone Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.45
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Milestone Pharmaceuticals has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Eyepoint Pharmaceuticals' return on equity of -135.81% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%

Summary

Eyepoint Pharmaceuticals beats Milestone Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Milestone Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MIST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MIST vs. The Competition

Export

Metric	Milestone Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$144.42M	$12.15B	$7.20B	$12.91B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	-1.68	787.65	273.16	25.45
Price / Sales	93.17	795.08	634.64	94.08
Price / Cash	N/A	91.95	76.74	53.00
Price / Book	7.73	11.97	12.98	6.14
Net Income	-$63.06M	$2.83B	$3.48B	$348.86M
7 Day Performance	9.95%	0.39%	0.13%	-0.80%
1 Month Performance	0.87%	5.34%	7.08%	4.13%
1 Year Performance	-36.96%	6.05%	24.67%	15.17%

Milestone Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MIST Milestone Pharmaceuticals	2.4602 of 5 stars	$1.16 -2.5%	$6.40 +451.7%	-37.0%	$144.42M	$1.55M	N/A	30
RLMD Relmada Therapeutics	2.6218 of 5 stars	$4.58 -0.1%	$12.00 +162.3%	+286.6%	$488.02M	N/A	N/A	10	Positive News
CGC Canopy Growth	0.8217 of 5 stars	$1.06 +0.5%	N/A	-44.5%	$474.01M	$251.01M	N/A	1,128	Analyst Upgrade
AVIR Atea Pharmaceuticals	2.2284 of 5 stars	$5.54 +0.6%	$7.00 +26.3%	+59.5%	$444.68M	N/A	N/A	70	Gap Down
BIOA BioAge Labs	3.8228 of 5 stars	$9.50 +1.3%	$36.57 +284.9%	+95.7%	$436.10M	$8.99M	N/A	N/A	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MIST) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Milestone Pharmaceuticals (MIST) Competitors

MIST vs. RLMD, CGC, AVIR, BIOA, and EYPT

How does Milestone Pharmaceuticals compare to Relmada Therapeutics?

Summary

How does Milestone Pharmaceuticals compare to Canopy Growth?

Summary

How does Milestone Pharmaceuticals compare to Atea Pharmaceuticals?

Summary

How does Milestone Pharmaceuticals compare to BioAge Labs?

Summary

How does Milestone Pharmaceuticals compare to Eyepoint Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIST vs. The Competition

Milestone Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Milestone Pharmaceuticals (MIST) Competitors

MIST vs. RLMD, CGC, AVIR, BIOA, and EYPT

How does Milestone Pharmaceuticals compare to Relmada Therapeutics?

Is MIST or RLMD more profitable?

Do insiders and institutionals hold more shares of MIST or RLMD?

Which has higher earnings and valuation, MIST or RLMD?

Which has more risk & volatility, MIST or RLMD?

Does the media refer more to MIST or RLMD?

Do analysts recommend MIST or RLMD?

Summary

How does Milestone Pharmaceuticals compare to Canopy Growth?

Which has more risk & volatility, CGC or MIST?

Does the media prefer CGC or MIST?

Do analysts prefer CGC or MIST?

Do institutionals & insiders have more ownership in CGC or MIST?

Is CGC or MIST more profitable?

Which has higher earnings & valuation, CGC or MIST?

Summary

How does Milestone Pharmaceuticals compare to Atea Pharmaceuticals?

Do analysts prefer MIST or AVIR?

Do insiders and institutionals hold more shares of MIST or AVIR?

Is MIST or AVIR more profitable?

Which has more volatility and risk, MIST or AVIR?

Which has higher valuation and earnings, MIST or AVIR?

Does the media favor MIST or AVIR?

Summary

How does Milestone Pharmaceuticals compare to BioAge Labs?

Do insiders & institutionals have more ownership in MIST or BIOA?

Is MIST or BIOA more profitable?

Do analysts recommend MIST or BIOA?

Which has higher earnings and valuation, MIST or BIOA?

Which has more risk and volatility, MIST or BIOA?

Does the media favor MIST or BIOA?

Summary

How does Milestone Pharmaceuticals compare to Eyepoint Pharmaceuticals?

Do institutionals and insiders have more ownership in EYPT or MIST?

Which has preferable valuation & earnings, EYPT or MIST?

Does the media prefer EYPT or MIST?

Which has more volatility and risk, EYPT or MIST?

Do analysts recommend EYPT or MIST?

Is EYPT or MIST more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIST vs. The Competition

Milestone Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools